Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results deaths Eclinical deterioration Ehospitalization E

COVID-19 (hospitalized or not) meta-analysis

Abu Esba LC (any NSAID use, acute and chronic) OBSnon-steroidal anti-inflammatory drugscontrolCOVID-19 (hospitalized or not)NA
146/357 safety concern -46% 49%
Gianfransesco OBSnon-steroidal anti-inflammatory drugscontrolCOVID-19 (hospitalized or not)NA
111/420 inconclusive -32%
Rinott OBSIbuprofencontrolCOVID-19 (hospitalized or not)NA
87/316 inconclusive 20%
Lund OBSnon-steroidal anti-inflammatory drugscontrolCOVID-19 (hospitalized or not)NA
248/8988 inconclusive 2% 14%

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons